News

PsiOxus wins biodefense contract
Enlarge image

BusinessUK

PsiOxus wins biodefense contract

18.01.2013 - British vaccine specialist PsiOxus Therapeutics Ltd. has baged a US$3.3m development contract from US Defense Threat Reduction Agency.

Under the terms of the agreement, the Oxford-based company will develop biodefence vaccine adjuvants. Using its PolyMAP platform, the company’s research will be aimed at improving safety and efficacy of two existing vaccine candidates: the recombinant protective antigen (rPA) against Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). A monoclonal antibody targeting Anthrax has been recently approved by the US FDA.

The contract will support work over a three-year period in the US, as well as in the company’s new laboratory in Oxford, which has been designed and equipped as a category two laboratory for the handling of live viruses.

PsiOxus Therapeutics’ PolyMAP technology links polymers to synthetic adjuvants that activate specific sets of Toll-like receptors (TRLs), which significantly boosts the effectiveness of vaccines in a controlled manner.

© eurobiotechnews/tg

http://www.european-biotechnology-news.com/news/news/2013-01/psioxus-therapeutics-wins-biodefense-contract.html

ResearchUK

30.01.2015 AstraZeneca has joined forces with four research collaborations to use breakthrough CRISPR gene editing technology across its drug discovery platform.

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.36 CHF9.09%
  • FORMYCON15.48 EUR8.25%
  • MAGFORCE5.18 EUR3.39%

FLOP

  • BB BIOTECH244.15 EUR-4.91%
  • CO.DON2.34 EUR-2.50%
  • MORPHOSYS76.24 EUR-1.78%

TOP

  • CYTOS0.36 CHF56.5%
  • FORMYCON15.48 EUR53.6%
  • ADDEX3.28 CHF41.4%

FLOP

  • BIOFRONTERA1.93 EUR-16.1%
  • ACTELION100.80 CHF-13.3%
  • MOLOGEN5.75 EUR-9.4%

TOP

  • SANTHERA105.00 CHF2558.2%
  • WILEX1.96 EUR168.5%
  • FORMYCON15.48 EUR103.7%

FLOP

  • CYTOS0.36 CHF-90.0%
  • 4SC0.84 EUR-49.7%
  • MOLOGEN5.75 EUR-49.7%

No liability assumed, Date: 29.01.2015